Fosun Pharma and Teva Pharmaceutical Industries side by side
Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.
At a glance
Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.
Pipeline by phase
Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.
| Furthest phase | Fosun Pharma | Teva Pharmaceutical Industries |
|---|---|---|
| Phase 1 | Fosun Pharma: 26 of its 48 programs at phase 1
and 21 more — sign in to see them all | 00% |
| Phase 2 | Fosun Pharma: 9 of its 48 programs at phase 2
and 4 more — sign in to see them all | Teva Pharmaceutical Industries: 1 of its 4 programs at phase 2
|
| Phase 3 | Fosun Pharma: 13 of its 48 programs at phase 3
and 8 more — sign in to see them all | 50% |
| Approved, new studies | 00% | Teva Pharmaceutical Industries: 1 of its 4 programs at approved, new studies
|
Readouts ahead
Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.
| Nov ’26 | Dec | Jan ’27 | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Fosun Pharma21 readouts · 3 phase 3 | Fosun Pharma, Nov ’26: 2 programs whose next study reaches primary completion
| Fosun Pharma, Dec ’26: 2 programs whose next study reaches primary completion
| Fosun Pharma, Jan ’27: 1 program whose next study reaches primary completion
| Fosun Pharma, Feb ’27: 1 program whose next study reaches primary completion
| Fosun Pharma, Mar ’27: 2 programs whose next study reaches primary completion
| Fosun Pharma, Apr ’27: 4 programs whose next study reaches primary completion, 2 in phase 3
| Fosun Pharma, May ’27: 1 program whose next study reaches primary completion
| Fosun Pharma, Jun ’27: 3 programs whose next study reaches primary completion, 1 in phase 3
| Fosun Pharma, Jul ’27: 1 program whose next study reaches primary completion
| Fosun Pharma, Aug ’27: 1 program whose next study reaches primary completion
| Fosun Pharma, Sep ’27: 3 programs whose next study reaches primary completion
| · |
| Teva Pharmaceutical Industries1 readouts · 0 phase 3 | · | · | Teva Pharmaceutical Industries, Jan ’27: 1 program whose next study reaches primary completion
| · | · | · | · | · | · | · | · | · |
Changed in the last 90 days
Since Aug 21, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.
Fosun Pharma
New programs 4
- HLX49phase 1 · first study · Nov 12
- FXS0260phase 1 · first study · Oct 25
- HLX109phase 1 · first study · Oct 18
- FXS4640phase 1 · first study · Sep 23
Reached a new phase 3
- FXR0906phase 2 · Oct 13
- HLX37phase 3 · Oct 4 · Carcinoma, Non-Small-Cell Lung
- FXS5626phase 3 · Sep 17 · Uveitis
Study stopped 0
None
Primary completion later 1
- Anti-PD-L1 Antibody-drug Conjugate HLX43phase 1 · Jun 2026 → Dec 2026 (+6 mo) · moved Oct 13 · NCT06115642
Teva Pharmaceutical Industries
New programs 0
None
Reached a new phase 1
- TEV-53408phase 3 · Oct 30 · Vitiligo
Study stopped 0
None
Primary completion later 0
None
Where they overlap
Conditions where at least two of them have programs: 1 in all. A program counts in each condition its studies name most.
| Condition | Fosun Pharma | Teva Pharmaceutical Industries |
|---|---|---|
| Vitiligoboth · compare here | Fosun Pharma in Vitiligo: 1 program
Their studies: Fosun Pharma’s studies of Vitiligo in search | Teva Pharmaceutical Industries in Vitiligo: 1 program
Their studies: Teva Pharmaceutical Industries’ studies of Vitiligo in search |
Same targetBetaPro · free during the beta
Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.
No gene two of them both target, among the programs whose target is known.
What this can't show
- Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
- Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
- Readout dates are the sponsors’ estimates, not results.
- A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
- “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.
- Programs a company names but has not registered are counted apart (Fosun Pharma: 18).